CASE FILE
Premium Grounding
Advertising Standards Authority (New Zealand) — Decision 25/261
Independent Scientific Evidence Reconstruction
This page presents the executive layer of the reconstruction. The complete 16-page evidence record is published separately as the authoritative document.
PROCEDURAL CONTEXT — EXTERNAL CASE RECORD
Jurisdiction
New Zealand
Authority
Advertising Standards Authority (ASA)
Decision
25/261
Case
Premium Grounding
Medium
Website
Outcome
Upheld
Procedural outcome — not a scientific finding.
INSPEKTORIUM RECONSTRUCTION
Evidence cut-off
22 August 2026
Reconstruction
23 August 2026
Version
v1.1
Independent research output. This page carries the executive layer; the complete 16-page evidence reconstruction is the authoritative record.
The public wording combines a real, measurable electrical phenomenon with much broader biochemical, therapeutic and product-specific claims. Human studies show that a configured conductive grounding path can alter measurable body voltage, potential or current. The available evidence does not establish the stronger advertised chain from Earth-origin electrons, through in-vivo free-radical neutralisation, to broad durable clinical benefits. Across sleep, pain, recovery, inflammation and other outcomes, the human literature contains genuine positive signals, direct null findings, surrogate-only results, small or uncontrolled studies, and important product/population transfer limits. The evidence therefore requires proposition-by-proposition resolution rather than a binary “works / does not work” conclusion.
INITIAL ASSESSMENT
An initial search found no material direct evidence for the menopause-related proposition.
REVISED ASSESSMENT
A later terminology-robustness check identified a relevant 2025 human study indexed primarily under “barefoot walking”. The evidence state was revised to VERY LIMITED DIRECT EVIDENCE — GROUNDING COMPONENT NOT ISOLABLE, and the change was preserved in the audit trail.
The study combines barefoot ground contact with walking, forest/nature exposure, instructor contact and plausibly social engagement, so it cannot isolate a grounding-specific effect.
The audit is designed to change when the evidence changes. A negative search result is not treated as proof of non-existence, and later retrieval can strengthen, weaken or qualify a prior assessment without being discarded as inconvenient.
Electrical grounding effect
SUPPORTED
Directly demonstrated at the level of measurable human voltage/current/potential under configured conductive contact.
BOUNDARY
Does not by itself establish molecular provenance, dose, tissue distribution or health benefit.
Earth-origin electrons / free radicals
SUPPORTED
Theoretical and indirect/nonhuman support exists.
BOUNDARY
No direct in-vivo human tracing of Earth-origin electrons or direct human radical-neutralisation assay was located.
Sleep
SUPPORTED
Several human studies report positive signals, including a small randomised pilot; other controlled comparisons are null or reporting-sensitive.
BOUNDARY
No exact-product, adequately powered, prospectively registered replication establishes broad sleep or insomnia benefit.
Pain
SUPPORTED
Positive controlled evidence exists in narrow settings, including induced muscle soreness and one-night postoperative pain.
BOUNDARY
These settings do not directly establish broad relief across aches, arthritis, back pain, neck pain and headaches.
Exercise recovery
SUPPORTED
Independent positive and null human studies exist.
BOUNDARY
Effects are protocol-, endpoint- and product-sensitive; no exact-product robust replication.
Inflammation / immunity
SUPPORTED
Multiple biomarker lines exist (CRP, cytokines, CK, IFN-gamma and related surrogates).
BOUNDARY
Biomarker change is not equivalent to treating inflammatory disease or improving functional immune competence.
Menopause symptoms
SUPPORTED
One condition-relevant human study was located.
BOUNDARY
Grounding is inseparable from walking, forest/nature, instructor-led delivery and plausibly social engagement; no product match.
Executive summary of the proposition-level assessment. The complete evidence record, including the individual studies behind each domain, is held in the full reconstruction.
A measurable lower-level effect can be real while a higher-level advertising claim still exceeds what was demonstrated. The audit therefore separates physical measurement, biological mechanism, biomarkers, clinical outcomes, durability and product generalisation.
LAYERS SEPARATED BY THE AUDIT
Physical measurement
Biological mechanism
Biomarkers
Clinical outcomes
Durability
Product generalisation
01
Measured electrical equalisation → assumed Earth-origin molecular electron flow.
02
Biomarker movement → assumed clinical anti-inflammatory or immune benefit.
03
Positive results in narrow experimental settings → broad claims across unrelated conditions.
04
Generic grounding interventions → assumed equivalence to an unidentified Premium Grounding product/configuration.
P01
P02
P03
P04
P05
P06
In H34, a nominally significant within-group change in one arm and a non-significant within-group change in the other do not establish a significant difference between groups.
“Difference in significance” is not “significance of the difference”.
THE COMPLETE CHAIN
Exact claim freeze → atomic decomposition → source-traceable evidence record → endpoint/population/timeframe/product fidelity checks → counterevidence → Steelman review → adversarial challenge → consistency review → frozen evidence substrate.
Scientific research was closed before adjudicative review; the ASA outcome was quarantined from scientific inference.
Exact 2025 Premium Grounding product/model/configuration was not recovered.
Some primary reports contain unresolved reporting contradictions.
H33 cannot isolate grounding from its co-interventions.
Some registered grounding studies remained unpublished, status-unknown or without located results at the evidence cut-off.
Bounded search saturation is not the same as claiming that the literature is complete.
Executive preview. The full reconstruction sets out the residual uncertainties in detail.
This document reconstructs the scientific evidence layer. It does not decide regulatory compliance, consumer interpretation, legal liability, or whether the ASA decision was correct.
Independent research output — not a review or reassessment of ASA Decision 25/261.
No ASA endorsement or affiliation is implied.
PDF · 291 KB
Complete proposition-level reconstruction, selected evidence record, residual uncertainties and method note.
Download PDF
Opens in a new tab.
Version 1.1 contains source-fidelity refinements to the description of the H33 intervention. The terminology was aligned more closely with the primary study’s documented forest-trail walking setting, and social engagement was distinguished from directly documented intervention components. No scientific conclusion or evidence classification changed. Evidence cut-off remains 22 August 2026.
Advertising Standards Authority (New Zealand), Decision 25/261, Premium Grounding, Website. Meeting 25 November 2025. Outcome: Upheld. Released 18 December 2025. Procedural record only.
INSPEKTORIUM (2026). Premium Grounding — Advertising Standards Authority (New Zealand) Decision 25/261: Independent Scientific Evidence Reconstruction. Version 1.1, evidence cut-off 22 August 2026.
Corrections, contradicting evidence and methodological challenges are welcome.